SCHEDULE: Prosight Entities Report Stake in Janux Therapeutics

Prosight Management, LP, along with affiliated entities and W. Lawrence Hawkins, have reported a combined beneficial ownership of 5.15% in Janux Therapeutics, Inc.

Summary

• This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership of Janux Therapeutics, Inc. common stock.
• The reporting persons include Prosight Management, LP, Prosight Fund, LP, Prosight Plus Fund, LP, Prosight Partners, LLC, and W. Lawrence Hawkins.
• W. Lawrence Hawkins, through his management roles in the Prosight entities, is deemed to beneficially own the reported shares.
• The total combined beneficial ownership reported by the Prosight entities and W. Lawrence Hawkins is 3,150,450 shares, representing 5.15% of the outstanding common stock.
• This ownership stake is based on 61,183,417 shares of common stock outstanding as of November 3rd, 2026, as disclosed in Janux Therapeutics' Form 10-Q filed on November 5th, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting ownership stakes and not containing operational or financial performance updates.

Positives

• The reporting entities have disclosed their ownership stake, providing transparency to the market.
• The filing indicates a significant, though not controlling, ownership position in Janux Therapeutics.

Negatives

• The filing does not provide any information regarding the reasons for acquiring or holding this stake, nor any strategic intentions.
• No financial performance data or operational updates for Janux Therapeutics are included in this filing.

Risks

• The filing does not explicitly state any risks associated with the ownership stake.
• Potential future changes in ownership by these entities could impact the stock price.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Janux Therapeutics' future performance.

Management Comments

• Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Act") or any other purpose, the beneficial owner of any securities covered by this statement.
• Each Reporting Person may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purpose of Section 13(d) or 13(g) of the Act.
• Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purpose of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant shareholders to report their stakes in publicly traded companies. This filing indicates that the Prosight entities and W. Lawrence Hawkins have taken a notable position in Janux Therapeutics, a biotechnology company.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership stakes.
• Management of Janux Therapeutics: Awareness of substantial beneficial ownership by Prosight entities.

Next Steps

• The reporting persons will continue to monitor their investment in Janux Therapeutics.
• Future filings will be made if there are further changes in beneficial ownership.

Key Dates

Keywords

Janux Therapeutics, Schedule 13G, Beneficial Ownership, Prosight Management, W. Lawrence Hawkins, Common Stock, Ownership Stake